Scholar Rock Holding Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Scholar Rock Holding Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 19, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 3, 2026 |
| FY2023 | Dec 31, 2022 | $33.19M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $18.82M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.40M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $20.49M | Mar 9, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($377.94M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($246.29M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($165.79M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($134.50M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($131.80M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($86.48M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($51.00M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($49.33M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($25.00M) | Mar 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($384.65M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($252.05M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($171.30M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($134.37M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($129.92M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($86.88M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($54.54M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($50.69M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($25.03M) | Mar 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.44M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $184.55M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $121.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $124.44M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $108.47M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $74.06M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $54.22M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $36.31M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $19.94M | Mar 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($300.04M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($200.95M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($145.23M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($132.69M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($126.79M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($60.27M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($63.12M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $24.57M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($21.74M) | Mar 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $602.0K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $98.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $71.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.06M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $5.25M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.09M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.12M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.49M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $361.0K | Mar 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $404.27M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $474.92M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $311.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $358.17M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $304.45M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $388.31M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $196.38M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $181.34M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $61.64M | Mar 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.78M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $106.29M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $85.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $97.93M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $132.37M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $127.54M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $83.48M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $74.71M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $5.93M | Mar 19, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.49M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $368.63M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $225.22M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $260.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $172.07M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $260.77M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $112.90M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $106.62M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($53.52M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($30.03M) | Mar 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.30B) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($922.72M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($676.42M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($510.63M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($376.13M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($244.33M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($157.85M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($106.85M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($57.53M) | Mar 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $323.53M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $177.88M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $101.86M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $103.28M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $212.84M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $160.36M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $36.31M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $115.07M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $56.46M | Mar 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $51.00M | Mar 19, 2024 |
| FY2022 | Dec 31, 2022 | $51.00M | Mar 7, 2023 |
| FY2021 | Dec 31, 2021 | $52.00M | Mar 7, 2022 |
| FY2020 | Dec 31, 2020 | $26.00M | Mar 9, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 108.46M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 93.82M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 75.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 51.67M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 35.21M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 34.15M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 29.79M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 26.22M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 3.97M | Mar 19, 2019 |